Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope you are right
This is gonna move like $DRUG.
Big $ is going to send this soon! Book it!
Multiple Skin cancer FDA approved drugs and deep late stage pipeline.
Cash flow positive near term with big drug indications coming to market!
Parabolic move is on the horizon.
2.5 Million floating shares nearly 70% owned by insiders and institutions 4 million dollar market
$BFRI
New 52 week high of $9.00= fair value for just the pipeline today 1100% ROI=45 million dollar market cap
Cash flow positive in the coming months Roth $16.00 Target last week.
They have one of 2 drugs on the market for a patient population of 13 million for pre cancerous legions the 3 tube = $1200 from $400 for 1 tube in one session approval accelerates revenue BFRI has the superior efficacy and safety record.. @ Xepi 2nd FDA approved drug. Never understood the ones who buy stocks after a parabolic move trend is changing.
Phase 3 Squamous cell carcinoma & basal cell carcinoma updates coming soon.
$20.00 price tag is in the cards the revenue next year should climb hence the 1-3 Tubes + in the coming quarters. + Late stage Phase 3's Skin cancer drugs that are safe and effective. Key Cash flow positive soon unheard of for a biotech under 5 million with a deep pipeline and nearing positive cash flow. Send it!
$BFRI
4 & half Million market cap 2.5 million floating the pipeline is worth 10x current price.
Institutions own 35%+
Insiders own 32%
The two FDA approved skin cancer drugs will make the company cash flow positive Q1 next year.
Reminds me of PLSE non revenue co a stock that can go from a $1.00-$20.00 in a blink of an eye.
Roth gave $16.00 PT last week.
Ameluz®
Ameluz® i approved for AK is the second most common diagnosis made by dermatologists in the United States
An estimated 13 million treatments given each year for AK in the US. Only one other drug is approved for this indication and is less effective and has side effects. Revenue should climb substantially after FDA approved 3 tubes in a single patient session instead of 1 tube $1200 instead of $400 not not all patients will need 3 tubes but figure at least half of them will.
Clinical trials must be conducted for further indications to be approved. Which trials are conducted for which new indications is a matter determined in close coordination with the FDA.
In the near future, Biofrontera is aiming for the US approval of Ameluz® for superficial basal cell carcinoma, acne, as well as new indications for actinic keratosis for areas beyond the face and scalp.
https://www.biofrontera-us.com/research/product-pipeline
BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed Approved by FDA
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation
2nd FDA approved drug XEPI® (ozenoxacin) Cream, 1% also approved by the FDA for the Treatment of Impetigo.
Multiple Clinical data updates coming Q4 2024 and Q1 2025
4.4 Million cap potential for 10-20x ROI from this level Cash flow positive early 2025 all outstanding debt has been paid off. The company is turning the corner timing is everything!
$BFRI
Revenue 35.24 Million
Quarterly Revenue Growth 34.00%
The Approval for 3 tubes from 1 tube per patient session will increase revenue drastically by 50%+.
https://finance.yahoo.com/news/fda-approves-three-tubes-biofrontera-124500388.html
Shares Outstanding 5.54M
Market Cap: 4.4 Million
Float 2.62M
% Held by Insiders 32.06%
% Held by Institutions 35.64%
Biofrontera raised an additional $8.0M in May 2024 from the exercise of warrants and has since paid down all outstanding debt
Pipeline Late stage Data updates in Q4 2024
https://www.biofrontera-us.com/research/product-pipeline
BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination Phase 3
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation
Cash Flow Positive Q1 2025 Tremendous upside potential from these levels at 4.4 Million market cap
$BFRI
2 FDA Approved Skin Cancer drugs.
Cash flow positive in 2025
All outstanding debt paid off.
Deep/Late stage Pipeline .
https://www.biofrontera-us.com/research/product-pipeline
Multiple data updates on the Superficial basal cell carcinoma & Squamous cell carcinoma by year end 2024.
Acne clinical data Q1 2025
$BFRI
$1.80-$2.00 Target 1 could happen in a blink of an eye.
Passes that 10-20x ROI seen these types of move happen dozens of time in 2024
Cash Flow positive in the coming quarters all outstanding debt paid off with a 13 million patient market they have 1 of 2 drugs approved by the FDA for this indication BFRI is more effective and saferr. Revenue 3x with the latest approval this week from 1 to 3 tubes being used in a single treatment each tube is roughly $400 now that translates into $1200 per patient late stage Pipeline alone is worth 10x the current market cap of 4 million! This company could get bought out by a big player pipeline is invaluable Acne and Skin Cancer markets are growing tremendously most drugs in late stage 3. Acne phase 2 70% of the shares are owned by Insiders and institutions
$BFRI
4 hour RSI Relative Strength Index 22.85. Market cap 3.9 Million
FDA approved drug with 13 Million patient market place and best in class RX for Ameluz®-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi® (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
News on the approval for 3 Tubes instead of 1 for a treatment is a big deal!
WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s sNDA to increase the maximally approved dosage from one to three tubes of Ameluz ® per treatment.
BFRI Pipeline
https://www.biofrontera-us.com/research/product-pipeline
BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed & Approved
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in Phase 3 (HUGE)
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing. (massive market)
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation. (Niche Market)
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing (key segment in skin disorders)
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation. (Billion dollar market)
This company can move a 1000% a still be undervalued. Roth analyst gave a $16.00 Target this week. Cash flow positive in 2025
Almost 60% shares locked up by insiders and Institutions 35 million in sales 34% YOY growth and 3 Tubes approval this week.
$BFRI
Sponging up shares RSI is extremely oversold!
Buy the fear and make the big $
$ 4 Million Micro cap with FDA approved skin cancer drugs with a deep late stage pipeline!
$BFRI
13 million patients for Ameluz® (aminolevulinic acid hydrochloride)
Topical gel, $1200 for 3 tubes 1st Line Best in class topical only one other drug on the market that has side effects and less effective.
“Up to 60% of squamous cell carcinomas begin as untreated AK lesions, so it’s important for us to be able to treat the entire affected field. I have used Ameluz ® now for more than 7 years for the management of AK because of the demonstrated efficacy and safety it delivers. With the approval of the sNDA, I look forward to being able to use up to three tubes for those patients that need them,” said Dr. Jonathan Weiss, investigator and co-managing partner at Georgia Dermatology Partners in Atlanta.
https://www.biofrontera-us.com/research/product-pipeline
Nearly 60% of the shares held by insiders and institutions revenues should drastically increase from the $1200 cost of 3 tubes the FDA has approved in a singles use compared to 1 tube which ran about $400.00
ROTH gave a $16.00 price target a few days ago Cash flow positive coming quarters!
3 days ago — Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $16.00 price target on Biofrontera (NASDAQ: BFRI).
$5.00 gap fill then $10.00+ Way Oversold on the RSI
$50 Million market is in line with their sales and massive growth + pipeline that will be seen in the coming quarters cash flow positive near team. 5 million market cap today.
$BFRI
Ameluz Skin Cancer Prevention prescription +PDT (Photodynamic Therapy)
Multiple suitors looking to acquire This is going to be funny when the buyout is announced!
The late stage pipeline has some very spectacular molecules for skin disease. Profitable Next Year!
Added 71k today on the fake red candle. Going to get aggressive here. Bears are going to get a sharp stick in the eye!
$BFRI
10x is possible here debt scrubbed profitable next year New Board member who is the largest shareholder
2 Million share float insiders and Tutues are up to 57% now
BFRI drug that just got approved for 3 tubes instead of 1 tube for their drug Ameluz
Estimated 13 million treatments given each year.
Each dose of Ameluz 10% topical gel is around $392.
Maximum dosage units is approximately $1,176.
That's a potential of 10 million additional units per treatment.
BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes ♦ Completed
BF-200 ALA Superficial basal cell carcinoma ♦ Last patient in
BF-200 ALA Moderate to severe acne ♦ Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities ♦ Phase III ongoing
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation
BFRI............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
BFRI..............................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
BFRI...............................................https://stockcharts.com/h-sc/ui?s=BFRI&p=W&b=5&g=0&id=p86431144783
awaiting pop from pp closing,restructure gives new hope,accumulation started fri,shares to short 60k(watching for decline)
This is what's really happing in the news:)
https://www.accesswire.com/viewarticle.aspx?id=835060
BFRI: Nice trick!!! (WOW, these firms are CLEVER!!!)
Word on the street is that BFRI is restructuring… laid off a significant number of sales reps today
I would stay away from this stock. If you do your due diligence Biofrontera (AG) & Inc in 25+ years have never turned a profit. Looking at BF AG …5/6 years ago the market cap was over $300 million. Look now at the combined market cap of Inc & AG. It’s a small fraction of that. Further, if you look at the Actinic Keratosis market and the players. The competitor dominates, other modalities are preferable. BF Inc would need $100 million minimum to get to profitability… and even then I don’t think it would. BF has raised about a quarter billion in 25+ years and still can’t turn a profit. It was recently announced that 2 investors bailed. My guess is that you will lose your shirt and everything else with this company. It’s poorly run!
$BFRI is up 60% after hours on no news.
Next chance mid October imo, the 13th
Definitely would want the share price to increase to its appropriate mean level (6.00 imo) to ease the pressure of the 87,000 IRS agents looking into movement of prices and the reasoning thereof, now that it appears the company was bought out getting back to a normal Shareprice could be a financial priority.
BFRI - 2 Friday
The last time a Friday was the 2nd day of the month was July 2, 2021. BFRI opened for trading October 29, 2021.
5 day consolidation completes in 5 minutes
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
441
|
Created
|
11/02/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |